Description: Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Home Page: www.revmed.com
700 Saginaw Drive
Redwood City,
CA
94063
United States
Phone:
650 481 6801
Officers
| Name | Title |
|---|---|
| Dr. Mark A. Goldsmith Ph.D. | CEO, President & Chairman |
| Mr. Jack Anders | Chief Financial Officer |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | President of Research & Development |
| Ms. Xiaolin Wang | Executive Vice President of Development |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board |
| Mr. Walter Reiher Ph.D. | Chief Information Officer |
| Ms. Jan Smith Ph.D. | Chief Scientific Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.52 |
| Price-to-Sales TTM: | 11206.309 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 490 |